We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 13, 2020

Activity and Safety of the Anti–PD-1 Antibody Dostarlimab for Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
JAMA Oncol 2020 Oct 01;[EPub Ahead of Print], A Oaknin, AV Tinker, L Gilbert, V Samouëlian, C Mathews, J Brown, MP Barretina-Ginesta, V Moreno, A Gravina, C Abdeddaim, S Banerjee, W Guo, H Danaee, E Im, R Sabatier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading